You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. New Technologies for Therapist Training and Patient Engagement in Behavioral Parent Training

    SBC: KOBAK, KENNETH A            Topic: 104

    Project Summary Abstract Behavioral parent trainingBPTis the gold standard treatment for disruptive behavior in preschool and elementary school age childrenDespite clear empirical evidence that it is effectiveadoption rates by practitioners remains woefully low due in part to a shortage of clinicians trained in BPTIn additioneven when BPT is administeredit is often done incorrectlyThe current stud ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Biomaterials for mRNA based cellular reprogramming

    SBC: Stem Pharm, Incorporated            Topic: 100

    Project Summary Abstract Induced pluripotent stem cells iPSCs hold great promise in the areas of disease modeling and regenerative medicine and as a result have unique commercial potential There are currently more than ongoing clinical trials in stem cell therapies including the first in human trial using human iPSC derived retinal pigment epithelial cells to treat ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. OpenBeds: Improving the Delivery of Care for Patients with Drug Addiction

    SBC: Openbeds Inc.            Topic: NIDA

    There is an urgent need for more effective mechanisms that leverage current technologies and best practices to both identify capacity and refer patients to drug treatment facilitiesThe applicant organizationOpenBeds Incis partnering with the non profit MESH Coalitionthree of the largest health care systems offering drug treatment in Indiana and the Indiana Division of Mental Health and AddictionDM ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomics' reduced genome E coli strains

    SBC: SCARAB GENOMICS, LLC            Topic: NIAID

    Scarab Genomics goal is to commercialize carrier proteins for conjugate vaccine manufacture This proposal focuses on two bacterial carrier proteins that have been approved by the FDA and that are in use in pre clinical and clinical studies Exoprotein A EPA from Pseudomonas aeruginosa and Protein D PD from non typeable Haemophilus influenzae These proteins are difficult to make by the conve ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Complete genome de novo assembly software for the emerging long read sequencing era

    SBC: DNASTAR, INC.            Topic: 400

    Despite the tremendous success of short read next generation sequencingNGStechnologiestheir inherent inability to establish long range connectivity makes fundamental tasks such as genome closurehaplotype phasing and alternatively spliced transcript characterization all but impossibleNowtwo long read sequencing providersPacific BiosciencesPacBioand Oxford Nanopore TechnologiesONTare producing data ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Restimulating memory T cell responses in elderly by a novel, live influenza vaccine

    SBC: Flugen, Inc.            Topic: NIAID

    Respiratory infections with influenza viruses cause severe morbidity and mortality in humans and animals worldwideImportantlyin humansthe majority of morbidity and mortality following flu infection is seen in older individualsrtyears oldYetclear understanding of how aging impacts on innate immune responsesand how to improve vaccine design in this age group is lackingRestimulating preexisting memor ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Non-pharmacological improvement of sleep structure in older people

    SBC: Mobile Sleep Technologies L.L.C            Topic: NIA

    ABSTRACT Poor sleep and memory problems are common in older adults and have considerable consequences including decreased productivitydeclines in cognitive abilitiesincreased rate of accidents and traffic fatalitiesand increased health care costsThese sleep and memory problems often occur in midlife and in older adultswhen aging is associated with insomniafragmentation of sleepand impairment of at ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. HTS Assays for Targeting the cGAS STING Pathway in Autoimmune Diseases and Cancer

    SBC: Bellbrook Labs, LLC            Topic: 300

    SUMMARY Cytoplasmic nucleic acids alert the immune system to invading pathogens and trigger a robust type I interferon IFN response via activation of the STING stimulator of interferon genes receptor The sensor for cytoplasmic nucleic acids was recently discovered to be a cyclic GMP AMP synthase which produces a unique cyclic dinucleotide second messenger cGAMP that serves as an agonist fo ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. High Fidelity Linear MicroVector to Clone Complex Problematic and Large DNAs

    SBC: VARIGEN BIOSCIENCES CORPORATION            Topic: 200

    The goal of this research is to dramatically improve the ability to clone and analyze large and unstable DNA fragments We propose to develop a novel linear cloning vector to maximize stability of cloned DNA in the bacterial host The vector will use the replication proteins of the phage Phi to achieve the highest accuracy of replication for all DNA inserts including AT rich repetitive or str ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Automation of MicroC as a CDx for myeloma therapies

    SBC: Lynx Biosciences, Inc.            Topic: 102

    Multiple myeloma MM is a debilitating and currently incurable hematological malignancy While the median survival has increased to years MM patients ultimately relapse and become resistant to therapy Once they reach this stage it is often a trial and error process until an effective therapy can be found Furthermore the MM bone marrow tumor microenvironment plays a significant role in ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government